Literature DB >> 31378814

Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics.

Alan D Lopez1, Tim Adair1.   

Abstract

BACKGROUND: The substantial decline in cardiovascular-disease (CVD) mortality in high-income countries has underpinned their increasing longevity over the past half-century. However, recent evidence suggests this long-term decline may have stagnated, and even reversed in younger populations. We assess recent CVD-mortality trends in high-income populations and discuss the findings in relation to trends in risk factors.
METHODS: We used vital statistics since 2000 for 23 high-income countries published in the World Health Organization Mortality Database. Age-standardized CVD death rates by sex for all ages, and at ages 35-74 years, were calculated and smoothed using LOWESS regression. Findings were contrasted with the Global Burden of Disease (GBD) Study.
RESULTS: The rate of decline in CVD mortality has slowed considerably in most countries in recent years for both males and females, particularly at ages 35-74 years. Based on the latest year of data, the decline in the CVD-mortality rate at ages 35-74 years was <2% (about half the annual average since 2000) for at least one sex in more than half the countries. In North America (US males and females, Canada females), the CVD-mortality rate even increased in the most recent year. The GBD Study estimates, after correcting for misdiagnoses, suggest an even more alarming reversal, with CVD death rates rising in seven countries for at least one sex in 2017. The rate of decline and initial level of CVD mortality appear largely unrelated.
CONCLUSIONS: A significant slowdown in CVD-mortality decline is now apparent across high-income countries with diverse epidemiological environments. High and increasing obesity levels, limited potential future gains from further reducing already low smoking prevalence, especially in English-speaking countries, and persistent inequalities in mortality risk pose significant challenges for public policy to promote better cardiovascular health.
© The Author(s) 2019; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.

Entities:  

Keywords:  Medical subject headings; cardiovascular diseases; cause of death; heart diseases; mortality; stroke

Year:  2019        PMID: 31378814     DOI: 10.1093/ije/dyz143

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  42 in total

1.  The Population Health OutcomEs aNd Information EXchange (PHOENIX) Program - A Transformative Approach to Reduce the Burden of Chronic Disease.

Authors:  Steven J Korzeniewski; Carla Bezold; Jason T Carbone; Shooshan Danagoulian; Bethany Foster; Dawn Misra; Maher M El-Masri; Dongxiao Zhu; Robert Welch; Lauren Meloche; Alex B Hill; Phillip Levy
Journal:  Online J Public Health Inform       Date:  2020-05-16

2.  Analysing the impact of modifiable risk factors on cardiovascular disease mortality in Brazil.

Authors:  Renato Simões Gaspar; Leandro F M Rezende; Francisco Rafael Martins Laurindo
Journal:  PLoS One       Date:  2022-06-22       Impact factor: 3.752

3.  Cardiovascular Risk Based on ASCVD and KDIGO Categories in Chinese Adults: A Nationwide, Population-Based, Prospective Cohort Study.

Authors:  Yu Xu; Mian Li; Guijun Qin; Jieli Lu; Li Yan; Min Xu; Tiange Wang; Zhiyun Zhao; Meng Dai; Di Zhang; Qin Wan; Yanan Huo; Lulu Chen; Lixin Shi; Ruying Hu; Xulei Tang; Qing Su; Xuefeng Yu; Yingfen Qin; Gang Chen; Zhengnan Gao; Guixia Wang; Feixia Shen; Zuojie Luo; Li Chen; Yuhong Chen; Yinfei Zhang; Chao Liu; Youmin Wang; Shengli Wu; Tao Yang; Qiang Li; Yufang Bi; Jiajun Zhao; Yiming Mu; Weiqing Wang; Guang Ning
Journal:  J Am Soc Nephrol       Date:  2021-03-04       Impact factor: 10.121

Review 4.  Global epidemiology of dyslipidaemias.

Authors:  Angela Pirillo; Manuela Casula; Elena Olmastroni; Giuseppe D Norata; Alberico L Catapano
Journal:  Nat Rev Cardiol       Date:  2021-04-08       Impact factor: 32.419

Review 5.  Physiological and clinical insights from reservoir-excess pressure analysis.

Authors:  Matthew K Armstrong; Martin G Schultz; Alun D Hughes; Dean S Picone; James E Sharman
Journal:  J Hum Hypertens       Date:  2021-03-09       Impact factor: 3.012

6.  Association of Non-High-Density Lipoprotein Cholesterol Measured in Adolescence, Young Adulthood, and Mid-Adulthood With Coronary Artery Calcification Measured in Mid-Adulthood.

Authors:  Matthew K Armstrong; Brooklyn J Fraser; Olli Hartiala; Marie-Jeanne Buscot; Markus Juonala; Feitong Wu; Juha Koskinen; Nina Hutri-Kähönen; Mika Kähönen; Tomi P Laitinen; Terho Lehtimäki; Jorma S A Viikari; Olli T Raitakari; Costan G Magnussen
Journal:  JAMA Cardiol       Date:  2021-06-01       Impact factor: 14.676

7.  The slowdown in the reduction rate of premature mortality from cardiovascular diseases puts the Americas at risk of achieving SDG 3.4: A population trend analysis of 37 countries from 1990 to 2017.

Authors:  Ramon Martinez; Patricia Soliz; Oscar J Mujica; Ludovic Reveiz; Norm R C Campbell; Pedro Ordunez
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08       Impact factor: 3.738

Review 8.  Five insights from the Global Burden of Disease Study 2019.

Authors: 
Journal:  Lancet       Date:  2020-10-17       Impact factor: 202.731

9.  Brief online certification course for measuring blood pressure with an automated blood pressure device. A free new resource to support World Hypertension Day Oct 17, 2020.

Authors:  Norm R C Campbell; Tej Khalsa; Pedro Ordunez; Yenny A Rodriguez Morales; Xin-Hua Zhang; Gianfranco Parati; Raj Padwal; Ross T Tsuyuki; Lyne Cloutier; James E Sharman
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-03       Impact factor: 3.738

10.  Investigating the association of testosterone with survival in men and women using a Mendelian randomization study in the UK Biobank.

Authors:  C M Schooling; J V Zhao
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.